Skip to main content
Matthew Gumbleton
( out of 14 reviews )

Matthew Gumbleton, MD, PhD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 1A, Thoracic
  • Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Patient Rating

    5.0 /5
    ( out of 14 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 13, 2023

    He seems to be. A great doctor and seems to really care.

  • Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Occupational Therapy
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Education history

    Postdoctoral Fellowship Huntsman Cancer Institute Postdoctoral Research Fellow
    Hematology & Medical Oncology - Huntsman Cancer Institute Fellow
    Residency Internal Medicine - University of Utah School of Medicine Resident
    Internal Medicine - University of Utah School of Medicine Intern/Resident
    Professional Medical Microbiology & Immunology - SUNY Upstate Medical University Norton College of Medicine M.D., Ph.D.
    Microbiology & Immunology - Kalamazoo College B.S.

    Selected Publications

    Journal Article

    1. Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta S (2023). A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC Res Notes, 16(1), 16. (Read full article)
    2. Gumbleton M, Sudan R, Fernandes S, Engelman RW, Russo CM, Chisholm JD, Kerr WG (2017). Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival. Sci Signal, 10(500). (Read full article)
    3. Iyer S, Brooks R, Gumbleton M, Kerr WG (2015). SHIP1-expressing mesenchymal stem cells regulate hematopoietic stem cell homeostasis and lineage commitment during aging. Stem Cells Dev, 24(9), 1073-81. (Read full article)
    4. Gumbleton M, Vivier E, Kerr WG (2015). SHIP1 intrinsically regulates NK cell signaling and education, resulting in tolerance of an MHC class I-mismatched bone marrow graft in mice. J Immunol, 194(6), 2847-54. (Read full article)
    5. Fernandes S, Brooks R, Gumbleton M, Park MY, Russo CM, Howard KT, Chisholm JD, Kerr WG (2015). SHIPi Enhances Autologous and Allogeneic Hematolymphoid Stem Cell Transplantation. EBioMedicine, 2(3), 205-213. (Read full article)
    6. Gumbleton M, Kerr WG (2013). Role of inositol phospholipid signaling in natural killer cell biology. Front Immunol, 4, 47. (Read full article)
    7. Fuhler GM, Brooks R, Toms B, Iyer S, Gengo EA, Park MY, Gumbleton M, Viernes DR, Chisholm JD, Kerr WG (2012). Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol Med, 18(1), 65-75. (Read full article)
    8. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova JL (2011). Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science, 332(6025), 65-8. (Read full article)


    1. William K, Gumbleton M (2020). Ship inhibition to induce activation of natural killer cells. U.S. Patent No. WO2015195812. Washington, D.C.:U.S. Patent and Trademark Office.
  • News & Podcasts